Combining a superoxide dismutase mimetic, avasopasem manganese, with stereotactic body radiation therapy may enable safe delivery of higher than standard radiation doses for patients with nonmetastatic, inoperable pancreatic adenocarcinoma. The phase Ib/II findings also suggest improved outcomes with avasopasem's addition, although the trial wasn't designed to compare arms and a larger study is needed.

You do not currently have access to this content.